Physician profile
Ronak Shah
NPI 1336402049
$2,241.27
in general payments reported to CMS, 2019-2025
26 companies · $1,260 in 2025
The $1,260 reported for 2025 was more than what 81% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $162 · 2020: $95.35 · 2021: $190 · 2022: $168 · 2023: $147 · 2024: $220 · 2025: $1,260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $765 · Food and Beverage: $702 · Consulting Fee: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $765.46 |
| Food and Beverage | $701.72 |
| Consulting Fee | $159.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Getinge USA Sales, LLC | $765.46 | 2025 | Vasoview Hemopro 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.64 | 2021-2025 | Ofev |
| Verathon INC. | $159.93 | 2025 | Video Laryngoscope |
| Glaxosmithkline, LLC. | $157.10 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Genentech USA, INC. | $124.77 | 2019 | |
| Inquis Medical, INC. | $119.27 | 2024-2025 | Aventus |
| Ambu INC. | $114.60 | 2025 | |
| Cumberland Pharmaceuticals, INC. | $95.35 | 2020 | |
| Abiomed | $87.27 | 2024 | Impella |
| Mylan Specialty L.P. | $48.38 | 2022 | |
| Mindray Ds USA, INC. | $47.49 | 2024 | Te X, Te7 Max |
| Incyte Corporation | $44.87 | 2022-2025 | Jakafi |
| La Jolla Pharmaceutical Company | $39.26 | 2025 | |
| Merck Sharp & Dohme LLC | $35.25 | 2022-2023 | Recarbrio, Zerbaxa, Dificid |
| Pfizer INC. | $32.00 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $29.79 | 2021 | |
| Boston Scientific Corporation | $22.62 | 2022 | |
| Beone Medicines USA, INC. | $22.42 | 2025 | Tevimbra |
| Olympus America INC. | $21.27 | 2019 | |
| Philips North America LLC | $20.00 | 2023 | |
| Grifols USA, LLC | $16.60 | 2022 | |
| Abbvie INC. | $15.89 | 2023 | Teflaro |
| United Therapeutics Corporation | $15.73 | 2023 | Tyvaso |
| Astrazeneca Pharmaceuticals LP | $15.65 | 2023 | Fasenra |
| Takeda Pharmaceuticals U.S.A., INC. | $14.95 | 2024 | Glassia |
| Jazz Pharmaceuticals INC. | $14.71 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronak Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.